Lennar Free cash flow decreased by 127.7% to -$463.49M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 34.3%, from -$345.09M to -$463.49M. Over 4 years (FY 2021 to FY 2025), Free cash flow shows a downward trend with a -67.3% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q1 '21 | Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $316.82M | $578.63M | $1.20B | -$78.01M | $119.76M | $482.17M | $2.68B | $972.78M | $634.63M | $929.52M | $2.54B | $294.94M | $202.95M | $800.84M | $933.14M | -$345.09M | -$1.11B | -$190.78M | $1.67B | -$463.49M |
| QoQ Change | — | +82.6% | +106.6% | -106.5% | +253.5% | +302.6% | +456.8% | -63.8% | -34.8% | +46.5% | +173.6% | -88.4% | -31.2% | +294.6% | +16.5% | -137.0% | -221.7% | +82.8% | +977.6% | -127.7% |
| YoY Change | — | — | — | — | -62.2% | -16.7% | +124.6% | >999% | +429.9% | +92.8% | -5.3% | -69.7% | -68.0% | -13.8% | -63.3% | -217.0% | -647.0% | -123.8% | +79.4% | -34.3% |